1223 related articles for article (PubMed ID: 28202013)
1. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
[TBL] [Abstract][Full Text] [Related]
2. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
Lee H; Hong SN; Min BH; Lee JH; Rhee PL; Lee YC; Kim JJ
Dig Liver Dis; 2015 Feb; 47(2):114-8. PubMed ID: 25467826
[TBL] [Abstract][Full Text] [Related]
3. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
[TBL] [Abstract][Full Text] [Related]
4. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
5. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
6. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
Pabón-Carrasco M; Keco-Huerga A; Castro-Fernández M; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Tepes B; Jonaitis L; Voynovan I; Lucendo AJ; Lanas Á; Martínez-Domínguez SJ; Almajano EA; Rodrigo L; Vologzanina L; Brglez Jurecic N; Denkovski M; Bujanda L; Abdulkhakov RA; Huguet JM; Fernández-Salazar L; Alcaide N; Velayos B; Silkanovna Sarsenbaeva A; Zaytsev O; Ilchishina T; Barrio J; Bakulin I; Perona M; Alekseenko S; Romano M; Gravina AG; Núñez Ó; Gómez Rodríguez BJ; Ledro-Cano D; Pellicano R; Bogomolov P; Domínguez-Cajal M; Almela P; Gomez-Camarero J; Bordin DS; Gasbarrini A; Kupčinskas J; Cano-Català A; Moreira L; Nyssen OP; Mégraud F; O'Morain C; Gisbert JP;
United European Gastroenterol J; 2024 Feb; 12(1):122-138. PubMed ID: 38050339
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital.
Dib J; Alvarez B; Mendez L; Cruz ME
Arab J Gastroenterol; 2013 Sep; 14(3):123-5. PubMed ID: 24206741
[TBL] [Abstract][Full Text] [Related]
8. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Rakici H; Ayaz T; Akdogan RA; Bedir R
Digestion; 2014; 90(4):261-4. PubMed ID: 25547786
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
Molina-Infante J; Perez-Gallardo B; Fernandez-Bermejo M; Hernandez-Alonso M; Vinagre G; Dueñas C; Mateos-Rodriguez JM; Gonzalez-Garcia G; Abadia EG; Gisbert JP
Aliment Pharmacol Ther; 2010 May; 31(10):1077-84. PubMed ID: 20180787
[TBL] [Abstract][Full Text] [Related]
10. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
[TBL] [Abstract][Full Text] [Related]
11. [Helicobacter pylori: what eradication regimen in a tropical area after the failure of two separate lines of eradication including metronidazole and clarithromycin?].
Razafimahefa SH; Rakotoarivelo RA; Andriamampionona TF; Rabenjanahary TH; Ramanampamonjy RM
Med Sante Trop; 2013; 23(1):108-9. PubMed ID: 23360589
[TBL] [Abstract][Full Text] [Related]
12. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
13. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
Romano M; Cuomo A; Gravina AG; Miranda A; Iovene MR; Tiso A; Sica M; Rocco A; Salerno R; Marmo R; Federico A; Nardone G
Gut; 2010 Nov; 59(11):1465-70. PubMed ID: 20947881
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
15. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
[TBL] [Abstract][Full Text] [Related]
16. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
Zhang W; Chen Q; Liang X; Liu W; Xiao S; Graham DY; Lu H
Gut; 2015 Nov; 64(11):1715-20. PubMed ID: 26338726
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
18. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection.
Alsohaibani F; Al Ashgar H; Al Kahtani K; Kagevi I; Peedikayil M; Alfadda A; Khan M
Saudi J Gastroenterol; 2015; 21(4):220-5. PubMed ID: 26228365
[TBL] [Abstract][Full Text] [Related]
19. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
[TBL] [Abstract][Full Text] [Related]
20. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
